Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
-
Publication number: 20130129646Abstract: The present invention relates to the cosmetic, dermatological or pharmaceutical (therapeutic) use of compounds of formula (I) or a cosmetically acceptable salt of a compound of formula (I) or a mixture containing two or more of these compounds or the salts thereof wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that a 3 to 8 membered ring is formed, for the lightening of skin and/or hair. The invention further relates to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) suitable for lightening human skin and/or hair and corresponding methods.Type: ApplicationFiled: May 25, 2010Publication date: May 23, 2013Inventors: Gabriele Vielhaber, Heiko Oertling, Karin Schaper, Claudia Gömann, Rahim Brodhage
-
Publication number: 20130121978Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.Type: ApplicationFiled: December 17, 2012Publication date: May 16, 2013Applicant: MARRONE BIO INNOVATIONS, INC.Inventor: Marrone Bio Innovations, Inc.
-
Publication number: 20130109712Abstract: The present invention relates to a statin for the use thereof for the prevention or treatment of drug addictions or in stopping drug consumption.Type: ApplicationFiled: April 5, 2011Publication date: May 2, 2013Applicants: Universite de Poitiers, Centre National De La Recherche ScientifiqueInventors: Marcello Solinas, Claudia Chauvet, Mohamed Jaber
-
Publication number: 20130096151Abstract: The present invention relates to the use of an anesthetic agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anesthetic agent and an antimicrobial agent for the treatment of microbial infections.Type: ApplicationFiled: March 29, 2011Publication date: April 18, 2013Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Yanmin Hu, Anthony M.R. Coates
-
Patent number: 8414958Abstract: What is described is an implant that comprises a coating, at least in areas, in the implanted state in the surface areas that are at least directly in contact with skin and/or soft tissue. The implant is preferably characterized in that the coating comprises both a statin, such as simvastatin, in the hydrolyzed or unhydrolyzed form, or pharmaceutically compatible salts thereof, as well as at least one other component selected from the group consisting of branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl, alkenyl, alkylaryl, aryl, cycloalkyl, alkylcycloalkyl, alkylcycloaryl amines or mixtures thereof and/or at least one water-soluble ionic polymer component. A method for production such an implant is also described as well as a composition that can be used in such a method.Type: GrantFiled: February 23, 2009Date of Patent: April 9, 2013Assignee: Thommen Medical AGInventors: Matthias Schnabelrauch, Armin Rex Kautz, Falko Schlottig
-
Publication number: 20130079310Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.Type: ApplicationFiled: August 13, 2012Publication date: March 28, 2013Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar SHAIKH, Jason YANTHA, Valerie SCHINI-KERTH
-
Publication number: 20130072509Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: ChromaDex Inc.Inventor: Jeremy Bartos
-
Publication number: 20130064892Abstract: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.Type: ApplicationFiled: September 8, 2011Publication date: March 14, 2013Inventors: Raed Hashaikeh, Hatem M.N. Abushammala
-
Publication number: 20130065924Abstract: A composition and method for the treatment of neurodegeneration and brain-derived neurotrophic factor. The composition and method comprising providing fluoxetine, simvastatin, and optionally, an antioxidant.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: WRIGHT STATE UNIVERSITYInventor: Adrian M. Corbett
-
Patent number: 8394851Abstract: The present invention discloses a method to inhibit a free radical, including a mitochondrial free radical, comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (I: a, b), an isomer, or a salt thereof:Type: GrantFiled: October 1, 2012Date of Patent: March 12, 2013Assignee: Island Kinetics, Inc.Inventors: Shyam K Gupta, Linda Walker
-
Publication number: 20130058904Abstract: A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.Type: ApplicationFiled: September 24, 2012Publication date: March 7, 2013Applicant: Francis Law GroupInventor: Robert G. Matheny
-
Patent number: 8383614Abstract: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.Type: GrantFiled: January 26, 2009Date of Patent: February 26, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Joseph A. Abboud, Louis J. Soslowsky
-
Patent number: 8383651Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.Type: GrantFiled: September 15, 2010Date of Patent: February 26, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Doris Riether, Renee M. Zindell, Patricia Amouzegh, Nigel James Blumire, Monika Ermann, Innocent Mushi, Robert John Scott
-
Publication number: 20130045217Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: ApplicationFiled: May 5, 2011Publication date: February 21, 2013Applicant: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Janis, Riika Katainen, Kirill Tarasov
-
Publication number: 20130046000Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: January 26, 2011Publication date: February 21, 2013Inventor: Naomi Kitamoto
-
Publication number: 20130045947Abstract: Materials and Methods are provided for the diagnosis, monitoring, and personalized treatments of gynecological cancers. The methods comprise determining levels of PLA2 activity in sample of tissue or fluid recovered from patient; elevated levels of PLA2 activity are consistent with epithelial ovarian cancer (EOC). These methods include assaying for PLA2 activity within tissue, ascites, blood, and other tissue forms by exposing the patient sample to a fluorogenic compound such as DBPC. The methods disclosed herein further include correlating the fluorogenic detection with a disease state in the patient, including diseases such as gynecological cancers, such as EOC. The methods comprise determining levels of total PLA2 activity, and of specific isoforms of PLA2 such as iPLA2, iPLA2?, cPLA2, among other isoforms.Type: ApplicationFiled: August 13, 2012Publication date: February 21, 2013Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventor: Yan Xu
-
Patent number: 8377918Abstract: Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers.Type: GrantFiled: January 31, 2006Date of Patent: February 19, 2013Assignee: ACC Therapeutics IncInventors: Bing-Hua Jiang, Jing Fang
-
Publication number: 20130040935Abstract: The invention relates to 5?-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.Type: ApplicationFiled: February 8, 2011Publication date: February 14, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ningshu Liu, Kai Thede, Philip Lienau, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Maher Najjar, Knut Eis, Reiner Fischer, Wahed Ahmed Moradi
-
Publication number: 20130040916Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: ApplicationFiled: October 12, 2012Publication date: February 14, 2013Applicant: ESPERION THERAPEUTICS, INC.Inventor: Esperion Therapeutics, Inc.
-
Patent number: 8372889Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.Type: GrantFiled: November 30, 2010Date of Patent: February 12, 2013Assignee: Omega Biopharma (I.P.3) LimitedInventors: Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
-
Publication number: 20130035304Abstract: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 31, 2011Publication date: February 7, 2013Inventors: Loren D. Walensky, Michelle L. Stewart, Nicole Cohen
-
Patent number: 8361972Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.Type: GrantFiled: June 21, 2012Date of Patent: January 29, 2013Assignee: Bristol Myers-Squibb CompanyInventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
-
Patent number: 8362086Abstract: The application relates to long acting injectable (LAI) formulations for combating ectoparasites and endoparasites in mammals. In particular, this invention provides for a LAI formulation comprising a subcutaneously volatile solvent, a biologically acceptable polymer, a bioactive agents and optionally one or more anti-ectoparasitically or anti-endoparasitically acceptable additive or excipient. Surprisingly, the liquid long acting injectable formulations of the invention solve the problems associates with previous injectable formulations by having long term stability, being able to accommodate smaller needle diameters and achieving long acting effects in the control of pests in a mammal. The unique formulations of the invention also allow for combating ectoparasites and endoparasites which have become resistant to macrolide antibiotics.Type: GrantFiled: August 19, 2005Date of Patent: January 29, 2013Assignee: Merial LimitedInventors: Mark D. Soll, Peter Hanson, Krishan Kumar, Monica Tejwani-Motwani
-
Publication number: 20130023513Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.Type: ApplicationFiled: January 11, 2011Publication date: January 24, 2013Inventor: Thomas E. Hughes
-
Publication number: 20130018023Abstract: The invention provides a composition comprising benzoyl peroxide or derivative thereof; and at least one antibiotic compound selected from pseudomonic acid, retapamulin, fusidic acid and derivatives thereof; methods and uses of a composition of the invention in the treatment of at least one topical disease or disorder and kits comprising a composition of the invention.Type: ApplicationFiled: March 24, 2011Publication date: January 17, 2013Applicant: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Karine Neimann, Braham Shroot
-
Publication number: 20130014428Abstract: Disclosed are methods which include exposing a beetle of the species Pityophthorus juglandis and/or treating surfaces susceptible to infestation by the species or to infection by Geosmithia morbida with compositions including one or more semiochemicals capable of being produced by Pityophthorus juglandis. The semiochemicals can be 3-methyl-2-buten-1-ol, conophthorin or chalcogran. Also disclosed are compositions and systems used in the methods.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Applicant: The United States of America as Represented by the Secretary of AgricultureInventors: Steven J. Seybold, Paul L. Dallara, Lori J. Nelson, Andrew D. Graves, Stacy M. Hishinuma, Regine Gries
-
Patent number: 8349889Abstract: The present invention relates to a topical skin-care preparation in the form of an ointment containing mupirocin and betamethasone dipropionate as active principles and a carrier formulated with all or some of the following components: hydrogenated castor oil, polyethylene glycols and preservatives. The inventive preparation is advantageous over prior art compositions in that it has a specific therapeutic effect on primary and secondary skin infections, such as relief of pruritic inflammatory manifestations of dermatosis, a wide range of activity against the majority of bacterial species involved in skin infections, and a high level of activity against Staphylococcus and Streptococcus, including multi-resistant strains. In addition, the therapeutic effect of the preparation is not affected by the size of the inoculum and the preparation has no sensitization potential, thereby providing the product with an excellent safety profile for use by the patient.Type: GrantFiled: September 28, 2005Date of Patent: January 8, 2013Assignee: Laboratorios Dermatologicos Darier, S.A. DE C.V.Inventors: Fernando Ahumada Ayala, Francisco Javier Padilla-Gomez
-
Patent number: 8349888Abstract: The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4?,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.Type: GrantFiled: January 29, 2010Date of Patent: January 8, 2013Assignees: The United States of America as represented by the Secretary Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Michael R. Landauer, Thomas Michael Seed, Venkataraman Srinivasan, Alla Shapiro, Chris H. Takimoto
-
Patent number: 8343943Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.Type: GrantFiled: December 6, 2006Date of Patent: January 1, 2013Assignee: National Cancer CenterInventors: Soo Youl Kim, Dae Seok Kim
-
Publication number: 20120329852Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Inventors: Mitsuhiro YOKOYAMA, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
-
Publication number: 20120329758Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.Type: ApplicationFiled: January 5, 2011Publication date: December 27, 2012Inventors: Yael Cohen, Niva Yacov, Eyal Breitbart
-
Publication number: 20120329787Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein Q, Z, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: June 22, 2011Publication date: December 27, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventor: THOMAS MARTIN STEVENSON
-
Patent number: 8338410Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.Type: GrantFiled: July 18, 2006Date of Patent: December 25, 2012Assignee: BiocodexInventors: Marc Verleye, Marie-Emmanuelle Le Guern, Philippe Girard, Jean-Marie Gillardin, Laurence Berthon-Cedille, Bernard Hublot
-
Publication number: 20120321609Abstract: A method of desensitizing 5-HT2R signaling in the mammal is provided. The method comprises one or more of: 1) inhibiting CRFR1 activation of 5-HT2AR signaling by preventing trafficking of intracellular vesicles or blocking recycling of 5-HT2AR to the cell surface; 2) blocking PDZ binding motifs in the carboxyl-terminal tail domains of at least one of CRFR1, 5-HT2AR or 5-HT2CR; or 3) blocking the interaction of a 5-HT2R or a CRFR1 with a PDZ-domain-containing protein selected from the group consisting of MAGI-1 PDZ1, MAGI-2 PDZ1, MAGI-3 PDZ1, PSD95 PDZ 1&2, PSD95 PDZ3, CAL PDZ, SAP97 PDZ 1&2, PTPN13 PDZ 4&5, PDZK2 PDZ1, MPP3 PDZ, ERBIN PDZ and MUPP1 PDZ 12.Type: ApplicationFiled: April 11, 2012Publication date: December 20, 2012Inventors: Stephen Ferguson, Ana Magalhaes, Hymie Anisman
-
Publication number: 20120315219Abstract: A coated medical device and a method of providing a coating on an implantable medical device result in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a therapeutic agent component can also be provided. The coated medical device is implantable in a patient to effect controlled delivery of the coating, including the therapeutic agent, to the patient.Type: ApplicationFiled: August 24, 2012Publication date: December 13, 2012Inventors: Roger Labrecque, Geoffrey Moodie, Joseph Ferraro, Lisa Rogers, Paul Martakos, Theodore Karwoski, Steve A. Herweck
-
Patent number: 8318771Abstract: Nephrogenic diabetes insipidus is treated with statins.Type: GrantFiled: July 30, 2010Date of Patent: November 27, 2012Assignee: Universita' Degli Studi di BariInventors: Giuseppe Procino, Maria Svelto, Giovanna Valenti, Monica Carmosino
-
Publication number: 20120282359Abstract: Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first composition comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a second composition comprising a soluble fiber. Even further described are compositions comprising a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors, HMG CoA synthase inhibitors, and mixtures thereof; and a soluble fiber.Type: ApplicationFiled: April 25, 2012Publication date: November 8, 2012Inventors: Abel Ennio Moreyra, Ashraf M. Koraym, Alan Chaney Wilson, Owen Rickford Carryl
-
Publication number: 20120282180Abstract: The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration.Type: ApplicationFiled: June 8, 2011Publication date: November 8, 2012Inventors: Hartmuth C. Kolb, Guenter Haufe, Malte Behrends, Klaus Kopka, Stefan Wagner, Verena Hugenberg, Hans-Joerg Breyholz, Sven Hermann, Michael Schaefers
-
Publication number: 20120283198Abstract: A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen, R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.Type: ApplicationFiled: July 2, 2012Publication date: November 8, 2012Applicant: SUZHOU HARMONY BIOTECHNOLOGY CO., LTD.Inventor: Hua MAO
-
Publication number: 20120283323Abstract: The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder.Type: ApplicationFiled: June 14, 2012Publication date: November 8, 2012Inventors: Alcino Silva, Yijun Cui, Weidong Li, Steven A. Kushner
-
Publication number: 20120276152Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.Type: ApplicationFiled: February 6, 2012Publication date: November 1, 2012Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
-
Publication number: 20120276204Abstract: The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.Type: ApplicationFiled: November 29, 2011Publication date: November 1, 2012Applicant: Neuropro Technologies, Inc.Inventors: Benjamin J. Remington, David J. Bearss, Kavian Shahi
-
Publication number: 20120270933Abstract: The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: MADEIRA THERAPEUTICSInventors: Ken Phelps, Jabar Qasem, Lynn Gold
-
Publication number: 20120258123Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.Type: ApplicationFiled: December 21, 2011Publication date: October 11, 2012Applicant: Zora Biosciences OyInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
-
Publication number: 20120252889Abstract: The present invention relates to a polyketide molecule of the following formula (I): or a pharmaceutically acceptable salt thereof, where R1 is a hydrogen atom or a (C1-C7) alkyl group, as well as the method of preparation and use thereof, in particular as an anticancer agent.Type: ApplicationFiled: October 28, 2010Publication date: October 4, 2012Applicants: PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)Inventors: Isabelle Carletti, Georges Massiot, Cécile Debitus
-
Patent number: 8278315Abstract: A method of treating living mammals including humans uses x-rays to disrupt DNA in malfunctioning cells such as cancerous or tumorous cells. A compound comprising a pre-selected element is administered to the mammal so that the compound associates with DNA. Then a localized region of cells which contains the malfunctioning cells is irradiated with line emission x-rays of an energy selected to cause emission of Auger electrons from the pre-selected element of the compound to disrupt DNA proximate to the irradiated pre-selected element. A kit useful for the treatment comprises an x-ray tube capable of emitting monochromatic line emission x-rays and a compound which associates with DNA and has an element which when irradiated emits said Auger electrons.Type: GrantFiled: August 28, 2003Date of Patent: October 2, 2012Inventor: Chia-Gee Wang
-
Patent number: 8278349Abstract: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.Type: GrantFiled: November 6, 2006Date of Patent: October 2, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Liat Goldberg, Michael Brownstein
-
Patent number: 8273791Abstract: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.Type: GrantFiled: December 10, 2008Date of Patent: September 25, 2012Assignee: JR Chem, LLCInventors: José E. Ramirez, Joseph R. Faryniarz
-
METHODS AND COMPOSITIONS FOR PROMOTING REGENERATION BY INCREASING INTRACELLULAR SODIUM CONCENTRATION
Publication number: 20120232000Abstract: The invention provides methods and compositions for increasing the intracellular sodium concentration in a cell.Type: ApplicationFiled: July 30, 2010Publication date: September 13, 2012Applicant: Tufts UniversityInventor: Michael Levin -
Publication number: 20120232033Abstract: The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Inventors: Sabine Kolczewski, Hans-Peter Marty, Robert Narquizian, Emmanuel Pinnard, Henri Stalder